Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic SARS-CoV-2 virus-specific T-cells
- Development stage
- Phase 2
- Lead developer
- Kalaris Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic SARS-CoV-2 virus-specific T-cells (VSTs) are an adoptive cellular therapy developed by the University of Edinburgh for the treatment of COVID-19. This therapy is manufactured using a single-stage process from the blood of individuals who have recovered from SARS-CoV-2 infection. The process selects and expands T-cells that are specifically reactive to viral antigens, such as the spike, nucleocapsid, and membrane proteins. When administered to patients with active COVID-19, these donor-derived T-cells are intended to recognize and eliminate virus-infected cells, thereby augmenting the recipient's immune response and potentially reducing disease severity. The therapy has been evaluated in the DEFINE platform trial (Phase Ib/IIa), which investigates various experimental treatments for hospitalized COVID-19 patients.
- Other names
- Allogeneic SARS-CoV-2 VSTsSARS-CoV-2 virus-specific T-cellsSARS-CoV2 virus-specific T-cellsSARS-CoV 2 virus-specific T-cellsAllogeneic SARS-CoV-2 virus-specific T-cells-University of Edinburgh-COVID-19
02
Targets
SARS-CoV-2 Spike peptide-HLA complexesSARS-CoV-2 nucleocapsid peptide-HLA complexespMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on allogeneic SARS-CoV-2 virus-specific T-cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic SARS-CoV-2 virus-specific T-cells.